Do Options Traders Know Something About Viemed Stock We Don't?
Investors need to pay close attention to VMD stock based on the movements in the options market lately.
Viemed Healthcare: Improving Capital Efficiency Creates A Strong Buy Opportunity
Viemed Healthcare (VMD) is evolving from a capital-intensive respiratory equipment company into a diversified, capital-light home healthcare provider. VMD's expansion into sleep, resupply, and women's health segments is driving robust revenue growth while reducing capital intensity and supporting free cash flow acceleration. Despite margin compression from the new business mix, VMD needs only 0.5% annual free cash flow growth to justify its current valuation, offering a strong margin of safety.
Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands
Viemed Healthcare NASDAQ: VMD outlined its growth strategy, product diversification and capital allocation priorities at the Midwest IDEAS Conference, emphasizing its focus on providing in-home care for patients with complex respiratory conditions.
Viemed Healthcare, Inc. (VMD) Q2 2026 Earnings Call Transcript
Viemed Healthcare, Inc. (VMD) Q2 2026 Earnings Call Transcript
Viemed Healthcare Q2 Earnings Call Highlights
Viemed Healthcare NASDAQ: VMD reported record second-quarter revenue as growth in its ventilator business resumed under the updated Medicare coverage framework and newer service lines expanded.
Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates
Viemed Healthcare, Inc. (VMD) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.08 per share a year ago.
Viemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call Transcript
Viemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call Transcript
Viemed Healthcare, Inc. (VMD) Q1 Earnings Miss Estimates
Viemed Healthcare, Inc. (VMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript
Viemed Healthcare: Remaining Bullish On Keen Valuation And Buoyant Cash Flow
Viemed Healthcare is reiterated as a 'Buy' due to robust revenue, earnings, and cash flow growth, alongside an expanding patient base. Q1 and Q2 2025 saw strong organic growth, with Lehan's acquisition quickly accretive and driving further patient count gains. Despite recently trimming FY2025 top-line guidance, VMD's valuation remains compelling with P/E, P/S, and P/B well below 5-year averages.
Viemed Healthcare, Inc. (VMD) Q2 2025 Earnings Call Transcript
Viemed Healthcare, Inc. (NASDAQ:VMD ) Q2 2025 Earnings Conference Call August 7, 2025 11:00 AM ET Company Participants Casey Hoyt - CEO & Director Trae Paul Fitzgerald - Chief Financial Officer William Todd Zehnder - COO & Director Conference Call Participants Ilya Zubkov - Freedom Broker, Research Division Ryan M. Langston - TD Cowen, Research Division Operator Greetings, and welcome to the Viemed Healthcare Second Quarter 2025 Earnings Call.
Viemed Healthcare, Inc. (VMD) Q1 2025 Earnings Call Transcript
Viemed Healthcare, Inc. (NASDAQ:VMD ) Q1 2025 Earnings Conference Call May 8, 2025 11:00 AM ET Company Participants Casey Hoyt – Chief Executive Officer Trae Fitzgerald – Chief Financial Officer Todd Zehnder – Chief Operating Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Ryan Langston – TD Cowen Andrew Rem – Odinson Partners Operator Good day, ladies and gentlemen, and welcome to the Viemed Healthcare First Quarter 2025 Earnings Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Trae Fitzgerald, CFO.
